Prime Medicine, INC Form 4 insider transactions

Prime Medicine, Inc. director David P. Schenkein acquired 75,000 stock options with an exercise price of $3.06, vesting under specific service conditions.

Prime Medicine, Inc. Director Jeffrey D. Marrazzo acquired 75,000 stock options with an exercise price of $3.06, vesting under specific service conditions.

Robert Nelsen, a Director and 10% owner of Prime Medicine, Inc., acquired 75,000 stock options on June 5, 2026.

Prime Medicine, Inc. reports that Director Michael Aaron Kelly was granted stock options for 75,000 shares.

Kaye I. Foster-Cheek, a Director at Prime Medicine, Inc., acquired 75,000 stock options.

Prime Medicine, Inc. reports that Director Wendy Chung acquired 75,000 stock options.

Prime Medicine, Inc. reports a Form 4 filing detailing the acquisition of stock options by Director Thomas Cahill.

Prime Medicine CFO Svetlana Makhni was granted 800,000 stock options with a strike price of $3.67, vesting over four years.

Prime Medicine, Inc. CEO and Director Allan Reine was granted 1.3 million stock options with an exercise price of $4.38, vesting monthly over four years.

Prime Medicine, Inc.'s Chief Technical Officer, Ann L. Lee, was granted 375,000 stock options with an exercise price of $3.34, vesting monthly over four years.

Prime Medicine's SVP, Finance and Chief Accounting Officer, Carman Alenson, was granted 140,000 stock options with an exercise price of $3.34.

Prime Medicine, Inc. has repriced certain outstanding stock options for its Chief Technical Officer, Lee Ann L., reducing the exercise price to $4.04 per share, effective August 1, 2025.

Prime Medicine, Inc. has repriced stock options for Director David P. Schenkein, lowering exercise prices to $4.04 per share.

Prime Medicine, Inc. has repriced certain outstanding stock options for Director and 10% Owner Robert Nelsen to an exercise price of $4.04 per share, effective August 1, 2025.

Prime Medicine, Inc. director Jeffrey D. Marrazzo's stock options were repriced to $4.04 per share, aligning with the company's closing stock price on August 1, 2025.

Prime Medicine, Inc. has repriced certain outstanding stock options for Director Michael Aaron Kelly to $4.04 per share, aligning with the closing market price on August 1, 2025.

Prime Medicine, Inc. has repriced stock options for Director Kaye I. Foster-Cheek, lowering the exercise price to $4.04 per share.

Prime Medicine, Inc. has repriced certain outstanding stock options for Director Wendy Chung to $4.04 per share, aligning with the current market price.

Prime Medicine, Inc. has repriced certain stock options for Director Thomas Cahill to $4.04 per share, aligning with the closing market price on August 1, 2025.

Prime Medicine, Inc. CEO Allan Reine's stock options were repriced to $4.04 per share following stockholder approval, reducing the exercise price from $6.80.

Prime Medicine, Inc. has repriced stock options for officer Carman Alenson, lowering the exercise price to $4.04 per share following stockholder approval.

GV 2021 GP, L.L.C., a 10% owner and director, acquired 1.5 million shares of Prime Medicine, Inc. common stock for $3.3 per share as part of a public offering.

Robert Nelsen, a Director and 10% owner of Prime Medicine, Inc. (PRME), has disclosed a planned acquisition of 3,030,300 shares of common stock valued at approximately $10 million, effective August 1, 2025.

ARCH Venture Partners, a significant shareholder and director, has increased its beneficial ownership in Prime Medicine, Inc. through a substantial common stock purchase.

ARCH Venture Partners, a significant insider and 10% owner, has disclosed a planned acquisition of over 3 million shares of Prime Medicine, Inc. common stock for approximately $10 million.

David R. Liu, a Director and 10% owner of Prime Medicine, Inc., reported the acquisition of 21,000 shares of common stock at a weighted-average price of $2.5157, effective June 30, 2025, under a Rule 10b5-1 trading plan.

David R. Liu, a Director and 10% Owner of Prime Medicine, Inc. (PRME), has acquired 21,000 shares of common stock, signaling increased confidence in the company.

Prime Medicine, Inc. Director and 10% owner David R. Liu acquired 21,000 shares of common stock for approximately $311,955 through a pre-arranged trading plan.

David R. Liu, a 10% owner and director of Prime Medicine, Inc. (PRME), has acquired 21,000 shares of common stock for approximately $33,589.50, executed under a pre-arranged Rule 10b5-1 trading plan.

Prime Medicine, Inc. Director David P. Schenkein was granted 55,000 stock options with an exercise price of $1.32 per share, vesting in 2026.